METTL3 and neoplasm: Patients with low levels of both METTL3 in tumour-infiltrating immune cells and CD33+ MDSCs were included in the combined low expression group, those with high levels of only one of the two biomarkers were included in the combined medium expression group, and those with high levels of both were included in the combined high expression group.